"Our greatest glory is not in never falling, but in rising every time we fall." -Confucius
Ellen
I know you, so I'm guessing that this surgery will take place sooner rather than later. If that OB-GYN gets in your way, I know you'll find a way around him. My money is on you, girl, start to finish. If you're convinced this is the way to go, then it will happen. Good luck today.
Love and big hugs,
Rita
Just know I will be with you for your appointments....I know you will make the right
decision.
Love and Hugs
Cathi
-§»§«:*´`³¤³´`*:» Vicky «:*´`³¤³´`*:»§«§-
"Our greatest glory is not in never falling, but in rising every time we fall." -Confucius
Ellen
Ellen,
I'm still looking into all of this myself. Here's some info I found on the web that might be of use:
Leisha A. Emens and Nancy E. Davidson
2
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Baltimore, Maryland 21231-1000
Abstract
Hormonal manipulation has been used for over 100 years to treat breast cancer. Ovarian ablation/suppression and tamoxifen are currently accepted adjuvant endocrine
therapies for premenopausal breast cancer. Methods of permanently ablating ovarian function include surgical oopho-rectomy and radiation-induced ovarian failure; medical
castration with luteinizing hormone-releasing hormone
analogues is a reversible approach. Adjuvant chemotherapy
frequently results in permanent amenorrhea and thus rep-
resents an indirect form of ovarian ablation. Although early
randomized trials of ovarian ablation suffered from small
sample sizes and design flaws, a meta-analysis of their re-
sults through the Early Breast Cancer Trialists’ Collabora-
tive Group demonstrated a clear benefit from ovarian abla-
tion as a single intervention in the adjuvant treatment of
women less than 50 years of age with breast cancer.
The ovary is the major site of estrogen production in the
premenopausal woman. A smaller amount of estrogen is pro-
duced as a result of the aromatase-mediated conversion of
androstenedione and testosterone to estrone and estradiol in
extragonadal tissues. In contrast, peripheral aromatization is the
primary source of estrogen in postmenopausal women. This
major difference in the means of estrogen production mandates
distinct strategies for disrupting its production in premenopausal
and postmenopausal women with breast cancer. Accordingly,
ovarian ablation/suppression is the most effective means of
decreasing estrogen production in premenopausal women,
whereas aromatase inhibition is emerging as the backbone of
hormonal therapy in postmenopausal women.
If you want ALL 27 pages, I can email it to you. I can't find the web link, but if you search under their names maybe it will come up.
Best of luck!
Erin